These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27010095)

  • 1. [The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod].
    Tanaka M
    Rinsho Shinkeigaku; 2016 Apr; 56(4):270-2. PubMed ID: 27010095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes zoster laryngitis in a patient treated with fingolimod.
    Hagiya H; Yoshida H; Shimizu M; Motooka D; Nakamura S; Iida T; Yamamoto N; Akeda Y; Tomono K
    J Infect Chemother; 2016 Dec; 22(12):830-832. PubMed ID: 27553068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
    J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
    JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
    Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes zoster: a potential risk associated with fingolimod treatment.
    Mayor Ibarguren A; Gómez Fernández C; Tallón Barranco A; Fernández Fournier M; González Ramos J; Romero Gómez MP; Herranz Pinto P
    Int J Dermatol; 2015 Sep; 54(9):e373-5. PubMed ID: 26173466
    [No Abstract]   [Full Text] [Related]  

  • 10. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
    Kawiorski MM; Viedma-Guiard E; Costa-Frossard L; Corral I
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):138-9. PubMed ID: 24958672
    [No Abstract]   [Full Text] [Related]  

  • 12. Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
    Marrone A; Signoriello E; Alfieri G; Dalla Mora L; Rinaldi L; Rainone I; Adinolfi LE; Lus G
    Infez Med; 2014 Dec; 22(4):331-6. PubMed ID: 25551852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
    Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
    Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
    Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder.
    Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W
    Mult Scler Relat Disord; 2016 May; 7():53-7. PubMed ID: 27237757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series.
    Signoriello E; Bonavita S; Sinisi L; Russo CV; Maniscalco GT; Casertano S; Saccà F; Lanzillo R; Morra VB; Lus G
    Mult Scler Relat Disord; 2020 May; 40():101963. PubMed ID: 31986424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.